EGFR and nasopharyngeal carcinoma: However, no large cohort study focusing on the prognostic factors of stage II-IVb NPC patients treated with anti-EGFR agents and IMRT, especially studies investigating whether adding extra concurrent chemotherapy to concurrent anti-EGFR therapy can significantly improve the survival of patients or not.